Market Intelligence, Clinical Progress, and High-Purity Reagents for Iron Metabolism Disorders.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TMPRSS6 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TMPRSS6 ECD-Fc / Protease Domain Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View TMPRSS6 Products |
| Mutant Control | TMPRSS6 S441A (Catalytic Dead) Mutant Protein For binding studies without enzymatic activity. Sequence Verified. |
View TMPRSS6 Products |
| Gene Delivery | TMPRSS6 Promise-ORF / Lentivirus Premade Particles Full-length ORF for stable hepatocyte cell lines. Purity >90%. |
View TMPRSS6 Products |
| Benchmark Ab | Anti-TMPRSS6 (Clinical Biosimilar Sequence / Preclinical Reference Clone) Recombinant positive control for binding/blocking. Sequence Verified. |
View TMPRSS6 Products |
| Validator | TMPRSS6 siRNA Set For knockdown verification and specificity controls. |
View TMPRSS6 Products |
| Substrate / Related Target | Hemojuvelin (HJV) Recombinant Protein Direct substrate; essential for hepcidin reporter and cleavage assays. Native glycosylation. |
View HJV Products |
| Pathway Partner | BMP6 Recombinant Protein Upstream regulator of hepcidin signaling. |
View BMP6 Products |
| Counter-Screening | TMPRSS2 Homolog Protein Paralog for subfamily selectivity and off-target counter-screening. |
View TMPRSS2 Products |
Critical Assay Challenges & TarMart Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protease Family Selectivity (vs TMPRSS2, TMPRSS3, Matriptase/ST14) | Homolog Panel Proteins (Human TMPRSS Family) strictly verified by mass spec; Sequence identity <60% for confident discrimination |
| Cross-species Cyno/Mouse Evaluation | Human/Mouse/Cyno ortholog TMPRSS6 ECD proteins available with >95% purity; Conserved catalytic domain alignment |
| Enzymatic Activity vs Binding Discrimination | Catalytic Dead (S441A) mutant paired with Wild-Type for mechanism-of-action studies |
| Cellular Hepcidin Response Validation | Lentivirus-transduced HepG2 cell lines with Endotoxin <0.1 EU/mL; Suitable for BMP6/Hepcidin reporter assays |
| Substrate Cleavage Specificity | Recombinant HJV protein with native glycosylation pattern for physiologically relevant cleavage kinetics |
Live TMPRSS6 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TMPRSS6-targeted therapeutics is intensifying, with major players shifting focus from traditional chelation and small-molecule inhibitors to liver-targeted genetic medicines (GalNAc-ASO/siRNA). Ionis Pharmaceuticals (IONIS-TMPRSS6-LRx, Phase II in polycythemia vera and β-thalassemia) and Silence Therapeutics (SLN124, Phase I/II) lead the nucleic acid modality. As first-generation therapies demonstrate hepcidin upregulation, the next wave includes combination approaches with erythropoietic agents (e.g., luspatercept) and expansion into NAFLD-associated iron overload, MDS, and sickle cell disease. Small molecule inhibitors and monoclonal antibodies are in preclinical stages, facing selectivity challenges against paralogs like TMPRSS2 and ST14.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| GalNAc-ASO / siRNA | Ionis / Disc Medicine, Silence Therapeutics | β-Thalassemia, Polycythemia Vera, Iron Overload | Hepatocyte stable line + hepcidin reporter (Need Lentivirus and validated siRNA) |
| Small Molecule Inhibitor | Preclinical academia / biotech | Hereditary Hemochromatosis, Iron Overload Disorders | Enzymatic inhibition kinetics (Need high-purity catalytic domain and mutant control) |
| Monoclonal Antibody | Early-stage biotech / academia | Hemochromatosis, Refractory Iron Overload | Blocking activity & internalization (Need ECD-Fc with native conformation) |
| Peptide Inhibitors | Specialty firms | Functional Iron Deficiency | Substrate competition assays (Need HJV cleavage validation) |
Key Mutations & Disease Relevance
TMPRSS6 loss-of-function mutations cause iron-refractory iron deficiency anemia (IRIDA), underscoring its role as a negative regulator of hepcidin. Key IRIDA-associated mutations include:
- Mutation A (dbSNP:rs199): Results in loss of proteolytic processing and activity.
- Mutation B (dbSNP:rs267607121): Reduces inhibition of the HAMP promoter, leading to elevated hepcidin.
- Mutation C (dbSNP:rs267607121): Impairs HJV-mediated inhibition of HAMP transcription; does not undergo proteolytic processing.
These mutations highlight the therapeutic potential of TMPRSS6 inhibition to increase hepcidin in iron-overload conditions. Their study requires recombinant mutant proteins and activity assays.
Molecular Differentiation & Assay Strategy
Selectivity Against Homologs
TMPRSS6 (matriptase-2) belongs to the type II transmembrane serine protease family. Catalytic domain homology with TMPRSS2, TMPRSS3, matriptase (ST14), and hepsin is 40–50%. Best-in-class candidates must demonstrate >100-fold selectivity to avoid off-target toxicity (e.g., TMPRSS2 affecting ACE2 cleavage and prostate). Counter-screening using a panel of recombinant homologs (available at TarMart) is essential.
Mechanism of Action
- Catalytic inhibition: Small molecules or antibodies directly blocking the serine protease active site (e.g., S441).
- Substrate competition: Blocking interaction with HJV.
- Expression knockdown: ASO/siRNA reducing TMPRSS6 mRNA levels.
Cellular Assays
- Hepcidin reporter assay: Huh7/HepG2 cells transduced with TMPRSS6 lentivirus + BMP6 stimulation; measure hepcidin promoter activity by luciferase.
- Protease cleavage assay: Recombinant HJV as substrate; detect cleavage by Western blot or FRET.
- Selectivity panel: Parallel testing against TMPRSS2, ST14, hepsin using enzymatic assays.
Related Target Recommendations (Cross-sell)
| Target | Rationale | Product Link |
|---|---|---|
| HJV (Hemojuvelin) | Direct substrate; cleavage assay gold standard | View HJV Products |
| BMP6 | Upstream positive stimulus for hepcidin signaling | View BMP6 Products |
| TMPRSS2 | Paralog for selectivity counter-screening | View TMPRSS2 Products |
| HAMP (Hepcidin) | Downstream effector; ELISA standard and reporter | View HAMP Products |
| SMAD4 | BMP/SMAD pathway core; mechanistic studies | View SMAD4 Products |